Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026
Pliant Therapeutics announced a poster presentation at ESMO Congress 2026 (Oct 23-27, Madrid) covering the FORTIFY Phase 1b indication expansion trial of PLN-101095. The poster will present Part 2 cohort expansion of a Phase I study of PLN-101095, a dual αvβ8/αvβ1 integrin inhibitor, combined with pembrolizumab in immune checkpoint inhibitor-refractory advanced solid tumors. FORTIFY is enrolling three cohorts (NSCLC, high tumor mutational burden, clear cell renal cell carcinoma), with PLN-101095 dosed at 1,000 mg twice daily before adding pembrolizumab.
Key figures
- Dose
- PLN-101095 1,000 mg twice daily
- Trial phase
- Phase 1a/1b
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.